Trials / Conditions / Relapsed AML
Relapsed AML
5 registered clinical trials studyying Relapsed AML.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Active Not Recruiting | CART123 + Ruxolitinib in Relapsed/Refractory AML NCT06768476 | University of Pennsylvania | Phase 1 |
| Unknown | An Early Phase Study of NEI-01 in Patients With Solid Tumors or Acute Myeloid Leukemia NCT05226468 | New Epsilon Innovation Limited | Phase 1 |
| Withdrawn | Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation NCT03560908 | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 |
| Terminated | Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia NCT03516760 | AvenCell Europe GmbH | Phase 1 |
| Completed | Phase 1 Study of Quizartinib NCT02675478 | Daiichi Sankyo Co., Ltd. | Phase 1 |